HoustonEcclestonHolmesIIIMDMBA FACP

Hematology • Dallas, TX

Hematologic Oncology

Physician

Join to view full profile

Dr. Holmes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Holmes' full profile

Already have an account?

Office
3410 Worth St
Dallas, TX 75246
Phone+1 214-370-1000

Fax+1 214-370-1026

Education & Training

The University of Texas at DallasMBA, 2013
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1993 - 1996
Baylor University Medical CenterResidency, Internal Medicine, 1990 - 1993
University of Texas Southwestern Medical SchoolClass of 1990
Stanford UniversityBS, Medical Microbiology, 1981 - 1985

Certifications & Licensure

TX State Medical License 1991 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Fellow (FACP) American College of Physicians, 2000
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) Start of enrollment: 2016 Mar 07
Completed
Phase 1, Phase 2
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Start of enrollment: 2017 Nov 27
Recruiting
Phase 1, Phase 2
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma Start of enrollment: 2019 May 07
Active, not recruiting
Phase 3
A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas Start of enrollment: 2018 Oct 23
Completed
Phase 3
Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Start of enrollment: 2018 Nov 15
Terminated
Phase 1
Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) Start of enrollment: 2019 Apr 16
Active, not recruiting
Phase 3
A Phase 1 Study of ADI-001 in B Cell Malignancies Start of enrollment: 2021 Mar 04
Recruiting
Phase 1
Roles: Contact
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Start of enrollment: 2021 Nov 12
Active, not recruiting
Phase 2
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

936 citations
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang, Javier Munoz, Andre Goy, Frederick L. Locke, Caron A. Jacobson
The New England Journal of Medicine. 2020-04-01
102 citations
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
Michael Wang, Javier Munoz, Andre Goy, Frederick L Locke, Caron A Jacobson
Journal of Clinical Oncology. 2023-01-20
97 citations
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
Bijal D. Shah, Michael R. Bishop, Olalekan O. Oluwole, Aaron C Logan, Maria R. Baer
Blood. 2021-07-08

Journal Articles

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Wang et al, New England Journal of Medicine, 4/2/2020

Abstracts/Posters

Product characteristics and pharmacological profile of KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in the phase II registration...
Wang et al, ASCO, 6/2020
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase...
Houston Holmes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refract...
Shah et al, ASCO, 6/2019
Outcomes of patients (pts) treated with prior blinatumomab (Blin) in ZUMA-3: A study of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) t cell therapy, in adult ...
Shah et al, ASCO, 6/2018
Join now to see all

Lectures

A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a No...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

US Oncology Research Announces Schedule of Presentations at the Virtual 2020 American Society of Hematology Annual Meeting and ExpositionDecember 2nd, 2020
Treating Cancer with Immunotherapy in DFW – One Year LaterJune 9th, 2019